The big any-day-now biotech news we’re keeping an eye on

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello, everyone. Damian here with the latest biotech startup to downsize, a novel idea in cancer treatment, and a few major catalysts on the calendar.

The need-to-know this morning

• Kyverna Therapeutics, a biotech developing CAR-T treatments for autoimmune diseases, filed for an initial public offering. Its lead product, called KYV-101, is a patient-specific, CD19-targeted cell therapy for lupus nephritis, currently in a mid-stage clinical trial.

A buzzy biotech cuts staff, acknowledges setbacks

Dewpoint Therapeutics, a biotech startup that has raised nearly $300 million, has laid off 15% of its staff and acknowledged a pair of high-profile partnerships fell apart.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In